A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.
This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.
This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.
Prerna Suri reports from New Delhi.